Merck KGaA stock: analysis & valuation

MRK.DEDrug Manufacturers - Specialty & GenericGermanyData as of Nov 15, 2026
Metrics analysis · Drug Manufacturers - Specialty & Generic

Merck KGaA MRK.DE

Price 149.60 EUR +0.98%Market cap 65.0 bn EUR52 weeks 100.70 – 156.25
Forward P/E
16.4x
Industry 13.1x
EV/EBITDA
12.0x
Industry 12.0x
Revenue growth
5.8%
Industry 7.3%
Operating margin
17.0%
Industry 16.8%
Return on equity
6.4%
Industry 7.4%
Free cash flow yield
3.4%
Industry 5.3%

What does Merck KGaA do?

Merck KGaA is a science and technology group from Darmstadt that operates in three areas: Life Science, Healthcare and Electronics. Life Science supplies reagents, consumables, instruments and services for research laboratories and biotech and pharmaceutical companies, including products for the manufacture of biopharmaceuticals as well as contract development and manufacturing.

The Healthcare business develops and markets prescription medicines, including in oncology, neurology and fertility. Electronics supplies specialty materials to the semiconductor and display industries. In competition, Merck is among the large global providers in the life science business alongside Thermo Fisher and Danaher. The company is broadly diversified but remains dependent in individual markets on established products and its own research pipeline. The Merck family, as owner, holds the majority of the capital and shapes the long-term direction.

Score profile

Quality4.7
Valuation3.2
Growth2.5
Financial strength4.8
Momentum8.4

Rank vs. Drug Manufacturers - Specialty & Generic (26 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.

Metrics compared with the industry

On profitability and quality, Merck KGaA ranks in the middle in the group Drug Manufacturers - Specialty & Generic (4.7/10). On growth, the company ranks below average in the group Drug Manufacturers - Specialty & Generic (2.5/10). On valuation (higher = cheaper), the stock ranks below average in the group Drug Manufacturers - Specialty & Generic (3.2/10). On financial strength, Merck KGaA ranks in the middle in the group Drug Manufacturers - Specialty & Generic (4.8/10).

MetricStockGroup medianRanking
Forward P/E16.4x13.1xbetter than 26 %
Trailing P/E33.9x20.5xbetter than 19 %
PEG ratio2.4x1.6xbetter than 18 %
EV/EBITDA12.0x12.0xbetter than 50 %
Price/sales3.0x2.2xbetter than 33 %
Price/book2.1x2.7xbetter than 63 %
Revenue growth5.8%7.3%better than 44 %
Earnings growth-49.8%0.0%better than 6 %
Gross margin59.0%63.0%better than 40 %
Operating margin17.0%16.8%better than 56 %
Net margin9.0%9.9%better than 48 %
Return on equity6.4%7.4%better than 44 %
Debt/equity38.1%84.6%better than 75 %
Current ratio1.7x2.1xbetter than 30 %
Free cash flow yield3.4%5.3%better than 38 %
Dividend yield1.5%2.3%–
Payout ratio49.8%31.8%–
Beta0.810.76–

Valuation: what is Merck KGaA worth?

Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give Merck KGaA a model range of 100.51 EUR to 161.84 EUR per share.

Price 149.60 EUR
Analysts 156.86 EUR
Fair value range 100.51 EUR – 161.84 EURMidpoint 127.80 EUR (−14.6% vs. price)

14 analysts, average rating “Buy”, average price target 156.86 EUR (+4.9%).

The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.

What the business depends on

  • Demand from biotech and pharmaceutical customers for process solutions and laboratory supplies largely determines growth in the Life Science business.
  • The success of medicines and the research pipeline in Healthcare influences the group's revenue and profitability.
  • Investment by semiconductor and display manufacturers drives capacity utilization and revenue in Electronics.

Risks

  • Patent expiries and competition from generics or biosimilars can significantly reduce revenues from established medicines.
  • Setbacks in clinical trials or approvals can devalue investments in the pipeline.
  • Cyclical demand in the electronics industry as well as exchange rate fluctuations weigh on earnings and predictability.

What to look for with Merck KGaA

Organic revenue growth by division is informative because it excludes currency and portfolio effects and makes the performance of the very different business areas comparable.

Full AI analysis of Merck KGaA

The AI evaluates all the numbers above and turns them into an assessment with a score, strengths and weaknesses, a fair value range and risks – from €1.99; Plus (€4.99) adds business model, moat and scenarios, Pro (€9.99) also peer comparison and reverse DCF. See an example.

Analyze a stock

Results in minutes
1 Choose a stock
2 Choose the depth

See what you get first: Example Compact (Apple) PDF Plus example (Microsoft) PDF Example Pro (NVIDIA) PDF

3 Delivery
Secure payment via Stripe Report by email + PDF No subscription

Frequently asked questions about Merck KGaA stock

What is the P/E ratio of Merck KGaA stock?

Based on expected earnings, Merck KGaA trades at a P/E of 16.4x, compared with a median of 13.1x for the peer group Drug Manufacturers - Specialty & Generic. Based on the earnings of the last twelve months it is 33.9x. (data as of Nov 15, 2026)

Does Merck KGaA pay a dividend?

Yes. The dividend yield is currently 1.5%, with a payout ratio of 49.8% of earnings.

Is Merck KGaA stock undervalued?

Measured by valuation metrics (P/E, EV/EBITDA, price/sales, PEG), Merck KGaA is currently valued more expensive than most companies in the group Drug Manufacturers - Specialty & Generic (valuation score 3.2 out of 10). Our model calculations (DCF and industry multiples) give a range of 100.51 EUR to 161.84 EUR per share at a price of 149.60 EUR. This is a model calculation, not an investment recommendation.

What do analysts say about Merck KGaA stock?

14 analysts have an average price target of 156.86 EUR (+4.9% vs. the current price); the average rating is “Buy”. Analyst targets are opinions and change frequently.

Comparable stocks

All information without guarantee. Metrics from public market data, updated daily; company profile written editorially with the help of AI. Not investment advice and not a solicitation to buy or sell securities.